

**OPTN Board Policy Group  
Meeting Summary  
November 7, 2024**

**Jennifer Muriett, Group Leader**

## **Introduction**

The Board Policy Group met via Webex on 11/07/2024 to discuss the following agenda items:

1. Welcome and Announcements
2. Revise Conditions for Access to the OPTN Computer System (Network Operations Oversight Committee)
3. Update Histocompatibility Membership Requirements (Histocompatibility Committee)
4. Require Reporting of HLA Critical Discrepancies and Crossmatching Events to the OPTN (Histocompatibility Committee)

### **1. Welcome and Announcements**

A subset of Board members met to discuss select items from the Summer 2024 Public Comment cycle to prepare for the December 2024 Board of Directors meeting. The following is a summary of the group's discussion.

Contractor staff explained next steps for the projects discussed during the meeting and other Summer 2024 public comment items. Board Policy Group members were asked to vote on their recommendation for agenda placement (discussion or consent) for the action items from the Network Operations Oversight Committee and the Histocompatibility Committee.

### **2. Revise Conditions for Access to the OPTN Computer System (Network Operations Oversight Committee)**

Andrew Kao, Chair of the Network Operations Oversight Committee (NOOC), presented the proposal to Revise Conditions for Access to the OPTN Computer System. Dr. Kao presented the purpose of the proposal, an analysis of public comment feedback, post-public comment changes made by the committee, and implementation considerations.

#### Summary of discussion:

Board members asked about details of the proposal including the 6-month timeframe for members to complete their Interconnection Security Agreements (ISAs) and how many business members the OPTN expected to be impacted by the policy. A Board member asked how the influx of business member applications could impact the Membership and Professional Standards Committee (MPSC) and whether the MPSC would be responsible for reviewing all new business membership applications. The Board Policy Group discussed the implementation of the policy and the information that has been shared with the MPSC to-date.

#### Vote:

The Board Policy Group voted 2 consent, 13 discussion, and 1 abstain on agenda placement for the proposal during the December 2024 Board meeting.

### **3. Update Histocompatibility Membership Requirements (Histocompatibility Committee)**

Gerald Morris, Chair of the Histocompatibility Committee, presented the proposal to Update Histocompatibility Membership Requirements. Dr. Morris shared the purpose of the proposal, public comment analysis, post-public comment change, and implementation considerations.

#### Summary of discussion:

A Board Policy Group member asked why the proposal would require more than one lab director and the rationale behind the committee including this provision. Dr. Morris explained that there will still be one primary lab director that would hold primary responsibility, however, the policy would require more than one director to be identified, due to an increase in lab complexity and volume.

#### Vote:

The Board Policy Group voted 15 consent and 0 discussion on agenda placement for the proposal.

### **4. Require Reporting of HLA Critical Discrepancies and Crossmatching Events to the OPTN (Histocompatibility Committee)**

Gerald Morris, Chair of the Histocompatibility Committee, presented the proposal to Require Reporting of HLA Critical Discrepancies and Crossmatching Events to the OPTN. Dr. Morris shared the purpose of the proposal, public comment analysis, post-public comment changes, and implantation considerations.

#### Summary of discussion:

Board Policy Group members asked clarifying questions about the policy, including the reporting of an event to the OPTN and the timeline the report must follow. Dr. Morris shared that events must be reported to the OPTN within 72 hours of the event. A Board Policy Group member asked why the committee changed the reporting timeline to the patient safety portal. Dr. Morris shared that the committee changed the reporting timeline to align with other OPTN policy requirements.

#### Vote:

The Board Policy Group voted 14 consent and 0 discussion on agenda placement for the proposal.

## Attendance

- **Group Members**
  - Andrea Tietjen
  - Andrew Kao
  - Catherine Kling
  - Christopher Jones
  - Colleen McCarthy
  - David Vega
  - Deborah Levine
  - Denise Abbey
  - Dev Desai
  - Emily Blumberg
  - Gaurav Gupta
  - Glen Kelley
  - Jennifer Muriett
  - Jennifer Reese
  - Macey Levan
  - Patrick Northup
  - Sara Rasmussen
- **HRSA Representatives**
- **UNOS Staff**
  - Anna Messmer
  - Cole Fox
  - Jamie Panko
  - Kaitlin Swanner
  - Morgan Jupe
  - Rebecca Murdock
  - Susan Tlusty
  - Susie Sprinson
- **Other Attendees**
  - Gerald Morris